FIELD: medicine.
SUBSTANCE: invention relates to medicine, particularly to medical genetics and gynecological oncology and is created to prognosticate the risk of ovarian cancer. DNA is isolated from lymphocytes of peripheral venous blood and complex detection of mutations c.5266dupC (BRCA1), c.181T>G (BRCA1), del5395 (CHEK2) and p.R145W (CHEK2) of a patient. Detection of one of the mentioned mutations indicates high risk of ovarian cancer. Invention provides a simpler method of identification of mutations c.5266dupC, c.181T>G (BRCA1), del5395 and p.R145W (CHEK2).
EFFECT: simplification of method of identification of mutations and reduction of research time to 1 day.
1 cl, 4 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DETERMINATION OF CANCER SUSCEPTIBILITY BY IDENTIFICATION OF GENOTYPIC COMBINATIONS OF SPECIFIC VERSIONS OF CYP1B1, BRCA2 AND CHEK2 GENES | 2006 |
|
RU2470998C2 |
| METHOD OF PREDICTING A LOW RISK OF DEVELOPING BREAST CANCER IN WOMEN WITH HIGHLY PENETRATING MUTATIONS IN THE BRCA1 AND CHEK2 GENES | 2022 |
|
RU2798666C1 |
| METHOD FOR PRE-IMPLANTATION GENETIC TESTING OF BREAST AND OVARIAN CANCER | 2021 |
|
RU2777091C1 |
| METHOD FOR PREDICTION OF RISK OF MALIGNANT DISEASES OF MAMMARY GLAND AND/OR OVARIES IN PATIENTS AFTER KIDNEY TRANSPLANTATION | 2023 |
|
RU2821583C1 |
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| METHOD FOR MOLECULAR-GENETIC DIAGNOSIS OF HEREDITARY BREAST CANCER | 2019 |
|
RU2702755C1 |
| METHOD FOR DETECTION OF BRCA1 5382insC AND CHEK2 1100delC MUTATIONS | 2011 |
|
RU2473700C2 |
| METHOD FOR BRCA1 AND BRCA2 GENES EXONS NUCLEOTIDE SEQUENCE DETERMINATION | 2015 |
|
RU2612894C1 |
| METHOD OF DIFFERENTIATED USE OF DNA SEQUENCING DATA FOR PATIENTS AFTER KIDNEY TRANSPLANTATION | 2022 |
|
RU2803796C1 |
| METHOD FOR IDENTIFYING RECESSIVE FACTORS OF GENETIC PREDISPOSITION TO BREAST CANCER | 2013 |
|
RU2535157C1 |
